Mayo Clinic Cardiovascular Education

Mayo Clinic is committed to taking care of our patients, learners and staff. Mayo Clinic Department of Cardiovascular Medicine education is actively planning livestream courses, webinars, and other virtual learning opportunities. We continue to closely monitor future in-person meetings as the CDC makes further recommendations. We’re happy to answer any questions you might have. Give us a call or send us an email and we’ll get back to you shortly. © 2025 Mayo Foundation for Medical Education and Research.

Read the full article here

Source: cveducation.mayo.edu

Categories: Hem/Oncs, General Medicine News

Tweets with this article

Thor Halfdanarson

Want to know more about carcinoid heart disease (CHD)? If so, you might find this webinar by members the Mayo CHD team informative. Dr's. Juan Crestanello (Cardiothoracic Surgery), S. Allen Luis (Cardiology) and then an oncologist... https://t.co/r5M9GbHdWq

Limitations of athlete-exposures as a construct for comparisons of injury rates by gender/sex: a narrative review

High rates of anterior cruciate ligament (ACL) injuries in girls’ and women’s sports have garnered significant attention from researchers, sport organisations and the media. Gender/sex…

Ash Paul January 11, 2025

SCLC: Treatment Overview and Treatment Landscape of Limited Stage – 2024 Lung Cancer OncTalk

The 2024 Lung Cancer OncTalk was a live, virtual, interactive patient education event presented in December 2024 and led by Dr. Ibiayi Dagogo-Jack. It includ…

H. Jack West, MD January 11, 2025

CDC Grant Funds Initiatives for Breast Cancer Patients

The five-year, $2.3 million grant from the Centers for Disease Control and Prevention will seek to improve equitable access to care, quality of life and…

Tatiana Prowell, MD January 11, 2025

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer | Pfizer

C linically meaningful and statistically significant results are the first pivotal Phase 3 data for sasanlimab, a subcutaneously administered PD-1 inhibitor If approved, sasanlimab would…

tompowles January 11, 2025

Financial Toxicity in Cancer Care: Where Are We, and How Did We Get Here? Introduction to a Special Series | JCO Oncology Practice

The first academic article using the term “financial toxicity” was published in 2013, 1 which catalyzed the growth of an emerging field of research and…

Ryan Nipp MD, MPH January 10, 2025

Pitfalls and perils from FDA-approved germ-line cancer predisposition tests – PubMed

The FDA approval on September 29, 2023, for “class III de novo” blood tests to assess hereditary cancer risk make widely available tests that may…

Wafik S. El-Deiry, MD, PhD, FACP January 10, 2025

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer | Pfizer

C linically meaningful and statistically significant results are the first pivotal Phase 3 data for sasanlimab, a subcutaneously administered PD-1 inhibitor If approved, sasanlimab would…

tompowles January 10, 2025

Related Articles